

Special Issue

Exploring the Genetic and Epigenetic Factors in Leukemia and Lymphoma

Message from the Guest Editor

Advancements in next-generation sequencing, chromatin conformation, and computational tools have deepened our understanding of genetic and epigenetic alterations in cancer. In the field of hematology, these alterations play a vital role in cell identity, differentiation, and transformation. To further our knowledge and develop personalized treatments, we invite you to contribute your original research to our Special Issue. We seek contributions on the molecular drivers of genetic and epigenetic aberrations, as well as strategies for their reversibility. This issue aims to highlight mechanistic approaches, discovery platforms, and diagnostic and therapeutic opportunities. We welcome original research articles and reviews, covering areas such as genetic and epigenetic alterations, gene regulation, computational analysis, and biomarker discovery. For any assistance, please reach out to us. We eagerly await your valuable submissions. Sincerely,

Guest Editor

Dr. Francesco E. Boccalatte
NYU Grossman School of Medicine, New York, NY, USA

Deadline for manuscript submissions

closed (31 July 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/200232

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)